Evelo’s Phase II Data Suggest Strong Position In Mild-To-Moderate Psoriasis

Analysts say biotech’s EDP1815 may offer similar efficacy to Amgen’s Otezla, with better safety. Evelo says data offer new proof for its small intestinal axis approach to inflammatory disease.

PSORIASIS Text, On Background of Medicaments Composition, Stethoscope, mix therapy drugs doctor flu antibiotic pharmacy medicine medical
Evelo candidate may offer relief for mild-to-moderate psoriais patients

Evelo Biosciences, Inc. unveiled Phase II data on 27 September indicating that its small intestinal axis-directed (SINTAX) therapeutic candidate EDP1815 can provide statistically significant clearance of psoriasis in mild-to-moderate cases with the safety profile of a placebo. The Cambridge, MA-based firm, a Flagship Pioneering portfolio company, says its SINTAX approach is differentiated from other microbiome therapies and may offer a new modality in immunology and other therapeutic areas.

The 249-patient study tested one-, four- and 10-capsule regimens of EDP1815 – an oral biologic that contains a single microbial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.

More from R&D

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire?

 

The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By 

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.